Johnson & Johnson JNJ

$270.47 +3.33 (1.25%)

Valuation

Market cap
643,088,832,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.61
P/E (forward)
24.53
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
11,925,300
Avg volume
7,611,122
Day's range
$269.47 – $272.50
Shares out
2,407,310,000
Stochastic %K
23%
Beta
0.22
Analysts
Moderate Buy
Price target
$283.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

StockBraker Nov 21, 10:10 PM
$JNJ Coming up on 2 years in Late January.
0 replies
inhomewindows Nov 21, 9:13 PM
$JNJ is p diddy released? That would up sales 30%
1 replies
ProjectBlackMoon Nov 21, 9:12 PM
$JNJ 😎
0 replies
Jbear236 Nov 21, 9:08 PM
$JNJ did diddy get released why is this trending?
2 replies
Gebinator Nov 21, 9:07 PM
$SLS Merck's been looking our way for nearly a decade! Ever since they partnered in 2017 on a 'basket study' evaluating GPS & Keytruda in combo. The protocol originally planned to enroll roughly 90 patients across five indications: ovarian cancer, colorectal cancer (mCRC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), & AML -- the study focused its clinical reporting only on the ovarian cancer cohort: ClinicalTrials.gov https://share.google/iT35vABb8MSqrCksm Trial records for NCT03761914 note planned cohorts such as SCLC and TNBC as "not opened". And Sellas itself didn't advance this GPS-Keytruda combo basket program on its own. This fact became fodder for $SLS Bears - who relentlessly argued Merck walked away and wasn't interested in GPS. Believe me - we long-term Longs lived through it. Merck used to be listed on the Sellas 'Partnerships' webpage, along with BMS - but both removed about the time Stacy Yeung was hired. Make of it what you will - as will $JNJ, $LLY & others.
1 replies
MysticChartReaderIQ69 Nov 21, 9:02 PM
$JNJ lolololol they are not buying SLS, retards
1 replies
BullBoardTrend Nov 21, 8:55 PM
$JNJ trending? ₿ull Board's weekly has been green since 07/14/25, ~65% higher since. Daily green since 10/26; only the 4H dipped red 11/19. Try it free for a month: https://bullboardtrend.com/?ref=stocktwits
0 replies
dewmoore Nov 21, 8:10 PM
We just had AWESOME news with $SLS—sitting at $2.8B–$2.9B market cap after Phase 3 REGAL and closing a $172.5M raise. I wanted $JNJ or $LLY … but honestly, it’s starting to sound like $MRK might be our new daddy 👀 Merck paid $6.7B for Terns back in March (which was only in Phase 1/2) to build out blood cancers. Then on Nov 17—the VERY SAME DAY $SLS dropped its Phase 3 REGAL news—$MRK pulled the plug on its Phase 3 blood-cancer drug because it was FAILING leaving a HUGE blood-cancer hole right when $SLS delivered. Look at the rest of the dots people are connecting: • Just like Terns months ahead of its deal, $SLS amended exec terms in June (lump-sum change-of-control shifts) + entered a quiet period • Just like Terns, $SLS raised millions ($172.5M closed) BEFORE any buyout—giving it cash leverage for FDA/BLA prep or Q1 pipeline moves! • Years of GPS + Keytruda history Hard not to wonder if Merck is looking our way. J&J and Lilly can watch from the sidelines 👀
1 replies